Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 8, 2011

View Archived Issues

Promising data described from several trials of natalizumab in RRMS

Incyte and Pfizer disclose favorable preclinical data on chemokine CCR2 receptor antagonist

Phase III results show immunogenicity of quadrivalent flu vaccine in children

Actilyse approved in 15 European countries to treat acute ischemic stroke

Nitazoxanide evaluated in viral respiratory infections

Researchers at Novartis disclose new kinesin-like protein KIF11 inhibitors

Novel candidate therapeutics prepared for ophthalmic diseases

Sanofi presents novel protease-activated PAR1 receptor antagonists

New MAP kinase p38 inhibitors designed by RespiVert

NanoViricides raises funds to advance new influenza candidate

Synageva BioPharma and Trimeris complete merger

Acadia Pharmaceuticals clear to test AM-831 in clinic

Novel HIV reverse transcriptase inhibitor prodrugs disclosed

Functional Genetics completes first-in-human FGI-101-1A6 trial

FDA recognizes Velcade extends survival of patients with multiple myeloma

NPS Pharmaceuticals reports topline results from phase III REPLACE study

Evolva clear to begin phase IIa development of EV-077 in diabetic complications

Daiichi Sankyo gains Brazilian rights to drug for overactive bladder

First RENAISSANCE phase III trial does not meet primary endpoint

Pilot study evaluates apremilast in ankylosing spondylitis

Novo Nordisk reports results from Japanese phase IIIa trial of DegludecPlus

FDA approves U.S. market return for Octagam

Artisan Pharma becomes wholly owned subsidiary of Asahi Kasei Pharma

Amgen to pay ImmunoGen milestone for use of TAP technology

Recordati's Normosang approved in Russia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...